ImmuneOnco signed licensing and CMO service agreements with Wo-Yun Investment LLP and Genor Biopharma (Yuxi, Yunnan, June 8, 2016)

“We are delighted to have Wo-Yun Investment Company as our first partner for co-developing the promising NK cell-based tumor immunotherapy”, said Dr. Wenzhi Tian, Chairman and Chief Executive Officer (CEO) of ImmuneOnco. “As the first battle line in preventin......

2016-06-08

ImmuneOnco secures 25 million RMB in pre-A round of fund-raising from Shanghai Zhangke Lingyi Investment Corporation

“Tumor immunotherapy is the hotspot in drug development, we are pleased to set up a tight collaboration with Dr. Tian who has much experience in antibody drug development. We believe our collaboration will definitely generate mutual benefit to both sides”, sai...

2015-12-12

The clinical data fraud crackdown

Nearly a month 10/13-11/13 biomedical industry index rose 12.39%, leading the CSI 300 index 2.40%, continued to rebound in the market after the National Day holiday. This month, small cap stocks rebound, such as crown Hao biological, Baida group, Benny pha......

2015-06-04

Biological medicine base service pilot through the pre acceptance

Beijing municipal quality and Technical Supervision Organization experts, a few days ago to the Daxing District national service industry standardization pilot project - Beijing Tai Hing bio pharmaceutical industry base comprehensive service standardization...

2015-04-14